Brandee L. Diamond

Partner

Brandee Diamond advises investors, corporate boards, and public and private companies in complex domestic and cross-border transactions in a range of industries, including life sciences, technology, food and beverage, apparel, print and digital media, and financial services. She is a partner based in the firm’s San Diego office, where she is a member of the Transactions Practice. Brandee also works closely with the firm’s Austin office.

With her distinguished background, Brandee has extensive experience with corporate mergers and acquisitions, dispositions, minority investments, joint ventures, and assisting with growth equity transactions, leveraged buyouts, going-private transactions, recapitalizations, and exits. She handles all aspects of the deal process, including working with corporate boards and senior management on pre-acquisition planning, transaction structuring, drafting, and negotiating acquisition and related agreements and post-acquisition integration planning.

In addition to her transactional work, Brandee counsels emerging growth companies across the full spectrum of the company’s lifecycle, encompassing formation and development, compensation, financing, and other corporate matters.

Representative Experience

  • Represented global private equity health care specialist ARCHIMED in its acquisition of Irrimax Corporation, including its holding company, Innovation Technologies, for an undisclosed sum. Irrimax develops and markets Irrisept® Antimicrobial Wound Lavage, a market-leading solution within high-performance wound irrigation.
  • Represented ARCHIMED in its acquisition of a majority stake in Cellese, a developer of innovative topical dermo cosmetics sold under the AnteAGE brand name, for an undisclosed sum.
  • Represented Matterport, Inc., a global leader in 3D digital twins and artificial intelligence for the real estate industry, in its proposed acquisition by CoStar Group for an estimated equity value of approximately $2.1 billion.
  • Represented Jelly Belly Candy Company in its sale to Ferrara Candy Company, for an undisclosed sum.
  • Represented Ascend Performance Materials in its acquisition of a majority stake in California-based Circular Polymers, a recycler of post-consumer, high-performance polymers including polyamide 6 and 66, polypropylene and polyester (PET), for an undisclosed sum.
  • Represented Riverwood Capital, a leading global investor in high-growth technology companies, as the lead investor in the $41 million growth funding round for One Model, a premier people analytics software company that provides organizations with state-of-the-art solutions to harness the power of their workforce data.
  • Represented MMGY Global, LLC, a Peninsula Fund company, in its acquisition of Wagstaff Media & Marketing, a leading integrated public relations and marketing agency specializing in the travel, culinary, and hospitality lifestyle industries, for an undisclosed sum.
  • Represented AltheaDx, Inc., a mental health diagnostics company, in its acquisition by Castle Biosciences, Inc., for initial consideration of $65 million, consisting of $32.5 million in cash and $32.5 million in common stock of Castle Biosciences, and additional consideration of up to $75 million in cash and common stock upon the achievement of certain milestones, including those based on certain expansions of Medicare coverage of IDgenetix, a pharmacogenomics test for depression, anxiety, and other mental health conditions.
  • Represented Fortress Information Security, a leading supply chain cybersecurity provider for critical infrastructure industries, in a $125 million strategic investment from funds managed by the private equity business within Goldman Sachs Asset Management.
  • Represented SoftBank Vision Fund in its US$300m investment in on-demand walking and dog care startup Wag.*
  • Represented software company, Twilio Inc., in its acquisition of Quiubas Mobile, an enterprise messaging provider in Mexico and LatAm.*
  • Represented Riverwood Capital, a growth equity firm that invests in high-growth middle market companies, in its growth equity investment in Forecast5 Analytics, the leading provider of decision support tools for local government administrators.*
  • Represented Centric Software, a venture capital-backed technology company, in its sale of a majority stake to Dassault Systèmes.*
  • Represented TubeMogul (NASDAQ:TUBE), an enterprise software company for digital branding, in its sale to Adobe through an all cash tender offer for US$540m.*

*Matters handled prior to joining Foley.

Affiliations

  • American Bar Association
  • M&A Committee of the Business Law Section
03 September 2024 Deals and Wins

Foley Represents ARCHIMED in Acquisition of Irrimax Corporation

Foley & Lardner LLP recently represented global private equity health care specialist ARCHIMED in its acquisition of Irrimax Corporation, including its holding company, Innovation Technologies, for an undisclosed sum.
22 May 2024 Events

MEMA OE Mobility Supplier Forum

Foley and MEMA Original Equipment Suppliers will host a Mobility Supplier Forum on May 22 and 23.
22 April 2024 Deals and Wins

Foley Represents AI Pioneer Matterport in Definitive Agreement to be Acquired by CoStar Group

Foley & Lardner LLP is representing Matterport, Inc. in its proposed acquisition by CoStar Group for an estimated equity value of approximately $2.1 billion and an enterprise value of approximately $1.6 billion.
11 April 2024 Deals and Wins

Foley Represents ARCHIMED in Acquisition of Majority Stake in Innovative Skincare Company Cellese

Foley & Lardner LLP represented global private equity health care specialist ARCHIMED in its acquisition of a majority stake in Cellese, a developer of innovative topical dermo cosmetics sold under the AnteAGE brand name.
30 January 2024 Foley Ignite

The Return of the Exit

Startups have found themselves pivoting significantly over the past year. Exit plans have either swiveled or been put on hold as valuations have remained low, and there has not been a huge market for M&A or IPOs.
24 January 2024 Deals and Wins

Foley Represents TCGX as Investor in Tourmaline Bio, Concurrent with Merger with Talaris Therapeutics

Foley & Lardner LLP represented TCGX as an investor in the $75 million private placement for Tourmaline Bio, concurrent with the company’s merger with Talaris Therapeutics.